Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the Worldwide Antimalarial Resistance Network (WWARN)

Chris Lourens, Niklas Lindegardh, Karen I Barnes, Philippe J Guerin, Carol H Sibley, Nicholas J White, Joel Tarning, Chris Lourens, Niklas Lindegardh, Karen I Barnes, Philippe J Guerin, Carol H Sibley, Nicholas J White, Joel Tarning

Abstract

Comprehensive assessment of antimalarial drug resistance should include measurements of antimalarial blood or plasma concentrations in clinical trials and in individual assessments of treatment failure so that true resistance can be differentiated from inadequate drug exposure. Pharmacometric modeling is necessary to assess pharmacokinetic-pharmacodynamic relationships in different populations to optimize dosing. To accomplish both effectively and to allow comparison of data from different laboratories, it is essential that drug concentration measurement is accurate. Proficiency testing (PT) of laboratory procedures is necessary for verification of assay results. Within the Worldwide Antimalarial Resistance Network (WWARN), the goal of the quality assurance/quality control (QA/QC) program is to facilitate and sustain high-quality antimalarial assays. The QA/QC program consists of an international PT program for pharmacology laboratories and a reference material (RM) program for the provision of antimalarial drug standards, metabolites, and internal standards for laboratory use. The RM program currently distributes accurately weighed quantities of antimalarial drug standards, metabolites, and internal standards to 44 pharmacology, in vitro, and drug quality testing laboratories. The pharmacology PT program has sent samples to eight laboratories in four rounds of testing. WWARN technical experts have provided advice for correcting identified problems to improve performance of subsequent analysis and ultimately improved the quality of data. Many participants have demonstrated substantial improvements over subsequent rounds of PT. The WWARN QA/QC program has improved the quality and value of antimalarial drug measurement in laboratories globally. It is a model that has potential to be applied to strengthening laboratories more widely and improving the therapeutics of other infectious diseases.

Copyright © 2014 Lourens et al.

Figures

FIG 1
FIG 1
Overall Z-scores over five rounds of proficiency testing (PT). The solid black line is a linear regression of all available Z-scores, with broken black lines indicating the 95% confidence interval. Results were scored as follows: |Z| ≤ 2, satisfactory; 2 < |Z| ≤ 3, questionable; and |Z| ≥ 3, unsatisfactory. Only seven laboratories analyzed this particular antimalarial compound (i.e., chloroquine).
FIG 2
FIG 2
Example of performance over three cycles of proficiency testing in a particular laboratory for four antimalarial compounds assayed. Results were scored as follows: |Z| ≤ 2, satisfactory; 2 < |Z| ≤ 3, questionable; and |Z| ≥ 3, unsatisfactory. Sample numbers refer to individual plasma samples per cycle.
FIG 3
FIG 3
Distribution map of pharmacology proficiency testing laboratories, in vitro laboratories, and drug quality testing laboratories (updated December 2013). All laboratories received reference materials.
FIG 4
FIG 4
Reference material vials with pierceable silicone/Teflon septa.

References

    1. Lourens C, Watkins WM, Barnes KI, Sibley CH, Guerin PJ, White NJ, Lindegardh N. 2010. Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN). Malar. J. 9:375. 10.1186/1475-2875-9-375
    1. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NPJ, McGready R, Ashton M, Nosten F, White NJ. 2008. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob. Agents Chemother. 52:1052–1061. 10.1128/AAC.00955-07
    1. Buick AR, Doig MV, Jeal SC, Land GS, McDowall RD. 1990. Method validation in the bioanalytical laboratory. J. Pharm. Biomed. Anal. 8:629-637. 10.1016/0731-7085(90)80093-5
    1. International Organization for Standardization. 2005. ISO/IEC 13528: statistical methods for use in proficiency testing by interlaboratory comparisons. International Organization for Standardization, Geneva, Switzerland
    1. Thompson M, Ellison SLR, Wood R. 2006. The international Harmonized Protocol for the proficiency testing of analytical chemistry laboratories (IUPAC technical report). Pure Appl. Chem. 78:145–196. 10.1351/pac200678010145
    1. Scorer TMP, Buckley M. 2004. Weighing in the pharmaceutical industry. Measurement good practice guide no. 70. National Physical Laboratory, Teddington, United Kingdom
    1. Hund E, Massart Luc D, Smeyers-Verbeke J. 2000. Inter-laboratory studies in analytical chemistry. Anal. Chim. Acta 423:145–165. 10.1016/S0003-2670(00)01115-6
    1. Prichard E, Barwick V. 2007. Quality assurance in analytical chemistry. John Wiley & Sons, Ltd., Hoboken, NJ
    1. Department of Science Services. Calibration report, laboratory no. L52/02129.1. Ministry of Science and Technology, Bangkok, Thailand
    1. Karkalousos P, Evangelopoulos A. 2011. Quality control in clinical laboratories, p 331–360 In Ivanov O. (ed), Applications and experiences of quality control. InTech, Rijeka, Croatia
    1. World Health Organization. 2011. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. World Health Organization, Geneva, Switzerland:
    1. Lindegardh N, Annerberg A, White NJ, Day NP. 2008. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 862:227–236. 10.1016/j.jchromb.2007.12.011
    1. Zaloumis S, Humberstone A, Charman SA, Price RN, Moehrle J, Gamo-Benito J, McCaw J, Jamsen KM, Smith K, Simpson JA. 2012. Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malar. J. 11:303. 10.1186/1475-2875-11-303

Source: PubMed

3
Iratkozz fel